用质子抑制剂治疗的血液恶性瘤患者的死亡率增加:一项全国性队列研究
Adam Vilmar1, Christian Dehlendorff2, Søren Friis3
1Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Leukemia & lymphoma
|June 9, 2023
概括
在患有血液性恶性瘤的患者中使用质子抑制剂 (PPI) 与更高的癌症死亡率有关. 这项研究建议在给癌症患者开处方PPI时谨慎行事.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 质子抑制剂 (PPI) 通常用于癌症患者预防胃问题.
- 以前的研究表明,PPI使用与固体瘤患者的死亡率增加之间存在联系.
- 抗血栓阻塞剂对血液恶性瘤死亡率的影响尚不清楚.
研究的目的:
- 为了研究后诊断质子抑制剂 (PPI) 使用和血液恶性瘤患者的死亡率之间的关联.
- 确定PPI使用是否会影响该患者群体的癌症特异性和非癌症死亡率.
主要方法:
- 这是一项大型的回顾性队列研究,利用丹麦全国卫生登记册.
- 包括15,320名被诊断患有血液性恶性瘤的患者.
- 在诊断后的1811名PPI使用者和非使用者之间比较死亡结果.
主要成果:
- 使用PPI的患者癌症特定死亡率的危险比率 (HR) 显著增加 (HR 1.31;95% CI,1.18-1.44).
- 在PPI使用者中观察到1年癌症特异性死亡率显著增加 (HR 1.50,95% CI 1.29-1.74).
- 这些发现表明PPI使用与血液恶性瘤患者不良死亡结果之间存在显著的关联.
结论:
- 诊断后的PPI使用与血液恶性瘤患者的癌症特异性死亡率增加有关.
- 这些发现支持了有关在癌症患者中广泛使用PPI的担忧.
- 进一步的研究可能是有必要的,以探索这种关联和替代管理策略背后的机制.
相关概念视频
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
475
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
475
01:26Peptic Ulcer Disease IV: Management
116
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
116
01:30Peptic Ulcer Disease I: Introduction
222
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
222
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
523
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
523
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
472
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
472
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
407
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
407